Every material Form 8-K Cryoport, Inc. has filed with the SEC since May 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cryoport reported third-quarter 2026 revenue of $50.2 million, up 14% from a year earlier, and raised its full-year 2026 revenue guidance to $197 million to $199 million. The company still posted a wider net loss attributable to common stockholders of $12.9 million, or $0.25 per share, compared with a $8.9 million loss, or $0.18 per share, in the prior-year quarter.
Q3 2026 total revenue was $50.2 million, up 14% year over year; Life Sciences Services rose 18% to $28.6 million.
Full-year 2026 revenue guidance was raised to $197 million to $199 million.
Q3 2026 net loss attributable to common stockholders was $12.9 million, or $0.25 per share, versus $8.9 million, or $0.18 per share, in Q3 2025.
Adjusted EBITDA from continuing operations was $1.1 million for Q3 2026, compared with a negative $0.6 million a year earlier.
Cryoport reported second-quarter 2026 revenue of $49.0 million, up 8% from $45.5 million a year earlier, and a loss from continuing operations that narrowed to $8.3 million from $12.0 million. Adjusted EBITDA from continuing operations was $0.4 million, compared with negative $0.9 million a year earlier. The year-ago period included a $120.9 million gain from the sale of the CRYOPDP courier business, so the reported net loss of $8.3 million compares with net income of $108.9 million in Q2 2025.
Q2 2026 total revenue was $49.0 million, up 8% year-over-year; Life Sciences Services revenue rose 15% to $28.0 million.
Loss from continuing operations was $8.3 million for Q2 2026, compared with $12.0 million for Q2 2025.
Total gross margin was 46.6% for Q2 2026, compared with 47.0% for Q2 2025.
Cryoport held $396.7 million in cash, cash equivalents, and short-term investments as of June 30, 2026.
Cryoport reported first-quarter 2026 revenue of $47.8 million, up 16% from a year earlier, and raised its full-year 2026 revenue guidance to $192 million to $196 million. Net loss narrowed to $10.5 million from $12.0 million, but the loss from continuing operations widened to $9.4 million from $6.7 million.
Q1 2026 total revenue was $47.8 million, up 16% year-over-year from $41.0 million.
Commercial cell and gene therapy revenue rose 26% to $9.1 million.
Net loss per share attributable to common stockholders was $0.25, compared with $0.28 in Q1 2025.
Cash, cash equivalents and short-term investments totaled $403.6 million as of March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cryoport, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →